MedTrace Logo

A Trial of Four Drug Regimens for the Prevention of Malaria in Senegalese Children

NCT00132548 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2200

Last updated 2017-01-12

No results posted yet for this study

Summary

A recent study has shown that the administration of a single dose of sulfadoxine/pyrimethamine plus artesunate to Senegalese children on three occasions during a short malaria transmission season reduced the incidence of clinical attacks of malaria by 86%. However, use of this drug regimen led to the selection of parasites with molecular markers of resistance to pyrimethamine and sulfadoxine. Therefore, a trial of three alternative regimens has been undertaken to see if these are as effective and safe as the drug combination used in the initial study but less likely to select for drug resistance.

Conditions

Interventions

DRUG

Pyrimethamine/sulfadoxine

DRUG

Amodiaquine

DRUG

Artesunate

Sponsors & Collaborators

  • Institut de Recherche pour le Developpement, Senegal

    collaborator OTHER

  • Cheikh Anta Diop University, Senegal

    collaborator OTHER

  • Ministry of Health, Senegal

    collaborator OTHER_GOV

  • London School of Hygiene and Tropical Medicine

    lead OTHER

Principal Investigators

  • Cheick Sokhna, PhD · Institut de Recherche pour le Developpement, Senegal

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Completion
2004-12-31

Countries

  • Senegal

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00132548 on ClinicalTrials.gov